These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36558928)

  • 1. Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets.
    Lee J; Park SB
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparative Clinical Pharmacology Analysis of FDA-Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology.
    Ngo HX; Wen YW; Pisupati S; Huang W; Mandlekar S
    Clin Pharmacol Ther; 2024 Jul; ():. PubMed ID: 39072721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in covalent warheads for in vivo targeting of endogenous proteins.
    Shindo N; Ojida A
    Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of targeted covalent inhibitors.
    Lonsdale R; Ward RA
    Chem Soc Rev; 2018 Jun; 47(11):3816-3830. PubMed ID: 29620097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Covalent Drug Discovery.
    Schaefer D; Cheng X
    Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics.
    Cheke RS; Kharkar PS
    Drug Dev Res; 2024 Feb; 85(1):e22132. PubMed ID: 38054744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ascension of Targeted Covalent Inhibitors.
    Singh J
    J Med Chem; 2022 Apr; 65(8):5886-5901. PubMed ID: 35439421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent Inhibition in Drug Discovery.
    Ghosh AK; Samanta I; Mondal A; Liu WR
    ChemMedChem; 2019 May; 14(9):889-906. PubMed ID: 30816012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design.
    Ray S; Murkin AS
    Biochemistry; 2019 Dec; 58(52):5234-5244. PubMed ID: 30990686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitriles: an attractive approach to the development of covalent inhibitors.
    Bonatto V; Lameiro RF; Rocho FR; Lameira J; Leitão A; Montanari CA
    RSC Med Chem; 2023 Feb; 14(2):201-217. PubMed ID: 36846367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Covalent Inhibitors for Drug Design.
    Baillie TA
    Angew Chem Int Ed Engl; 2016 Oct; 55(43):13408-13421. PubMed ID: 27539547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent applications of covalent chemistries in protein-protein interaction inhibitors.
    Chan AM; Goodis CC; Pommier EG; Fletcher S
    RSC Med Chem; 2022 Aug; 13(8):921-928. PubMed ID: 36092144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10 years into the resurgence of covalent drugs.
    De Vita E
    Future Med Chem; 2021 Jan; 13(2):193-210. PubMed ID: 33275063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
    Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
    Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.
    Yang J; Tabuchi Y; Katsuki R; Taki M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimagining Druggability Using Chemoproteomic Platforms.
    Spradlin JN; Zhang E; Nomura DK
    Acc Chem Res; 2021 Apr; 54(7):1801-1813. PubMed ID: 33733731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
    Yang Y; Shu YZ; Humphreys WG
    Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.